## INDEPENDENT AUDITORS' REPORT

## TO THE MEMBERS OF ZYDUS STRATEGIC INVESTMENTS LIMITED

## Report on the Audit of the financial statements

## Opinion

We have audited the accompanying financial statements of Zydus Strategic Investments Limited ("the Company"), which comprise the Balance sheet as at 31<sup>st</sup> March 2023, the Statement of Profit and Loss and the statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid financial statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at 31<sup>st</sup> March, 2023, its profit and its cash flows for the year ended on that date.

# **Basis for Opinion**

We conducted our audit of the financial statements in accordance with the Standards on Auditing ('SAs') specified under section 143(10) of the Act. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the financial statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on the financial statements.

# Information other than the Financial Statements and Auditor's Report thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the information included in the Board's Report, but does not include the financial statements and our audit reports thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

# Management's Responsibility for the financial statements

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these financial statements that give a true and fair view of the financial position, financial performance and cash flows of the Company in accordance with the Accounting Standards and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and

presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those Board of Directors is also responsible for overseeing the Company's financial reporting process.

# Auditor's Responsibilities for the Audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

## **Report on Other Legal and Regulatory Requirements**

As required by the Companies (Auditor's Report) Order, 2020 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Act, we give in the "Annexure A" a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- b) In our opinion, proper books of account as required by law have been kept, so far as it appears from our examination of those books. The backup of the books and account and other books and papers maintained in electronic mode, has been maintained on a daily basis on servers physically located in India during the year.
- c) The Balance Sheet, the Statement of Profit and Loss and Cash Flow Statement dealt with by this report are in agreement with the books of account.
- d) In our opinion, the aforesaid financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- e) On the basis of the written representations received from the directors as on March 31, 2023 taken on record by the Board of Directors, none of the directors, is disqualified as on March 31, 2023 from being appointed as a director in terms of section 164(2) of the Act.
- f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B" attached to this report. Our report expresses an unmodified opinion on the adequacy and operating effectiveness of the Company's internal financial controls over financial reporting.
- g) With respect to the other matters to be included in the Auditor's report in accordance with the requirements of section 197(16) of the Act, as amended, in our opinion and to the best of our information and according to the explanations given to us, no remuneration paid by the Company to its directors during the year.
- h) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:
  - i. The Company does not have any pending litigations which would impact its financial position.
  - ii. The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - iii. There has been no delay in transferring amounts, required to be transferred, to the Investor Education and Protection Fund by the Company.
  - v. (a) The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall, whether, directly or indirectly lend to or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries;

- (b) The management has represented that, to the best of its knowledge and belief, no funds have been received by the company from any persons or entities, including foreign entities ("Funding Parties"), with the understanding, whether recorded in writing or otherwise, that the company shall, whether, directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the Funding Party ("Ultimate Beneficiaries") or provide any guarantee, security or the like on behalf of the Ultimate Beneficiaries; and
- (c) Based on such audit procedures that we have considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations given under (a) and (b) above, contain any material misstatement.
- v. During the year, the company has not declared any dividends. Hence, reporting of compliance under section 123 of the Companies Act, 2013 is not applicable.
- i) As per the proviso to Rule 3(1) of the Companies (Accounts) Rules ,2014 (as amended), which provides for maintaining books of account in accounting software having a feature of recording audit trail of each and every transaction, creating an edit log of each change made in the books of account along with the date when such changes were made and ensuring that audit trail cannot be disabled, is applicable to the company only with effect from financial year beginning April 1,2023 ,the reporting under clause (g) of Rule 11 of the companies (Audit and Auditors)Rules ,2014 (as amended), is currently not applicable.

For **MUKESH M. SHAH & CO.,** Chartered Accountants Firm Registration No.: 106625W

Firm Registration No., 100023

Sd/-

Karnik K. Shah

Partner

Membership No.: 129675

Place: Ahmedabad Date: 29<sup>th</sup> April, 2023

UDIN: 23129675BGXDTE4095

## "Annexure A" to the Independent Auditors' Report

The Annexure referred to in Independent Auditors' Report to the members of the Company on the financial statements for the year ended March 31, 2023.

Based on the audit procedures performed for the purpose of reporting a true and fair view on the financial statements of the Company and taking into consideration the information and explanations given to us and the books of account and other records examined by us in the normal course of audit, we report that:

- 1. The Company does not hold any fixed assets hence clause (i)(a), (i)(b), (i)(c), (i)(d) and (i)(e) of paragraph 3 of the order are not applicable to the company for the year under audit.
- 2. (a) The company does not deal in any inventory; hence, this clause is not applicable to the company for the year under review.
  - (b) According to the information and explanations given to us and based on the records examined by us, the Company has not been sanctioned any working capital facility from banks or financial institutions in excess of five crore rupees, in aggregate, on the basis of security of current assets. Accordingly, reporting under clause (ii)(b) of the order is not applicable.
- 3. The company has not granted any loan, secured or unsecured, to the companies, firms or other parties covered in the register maintained under Section 189 of the companies Act, 2013.
- 4. According to the information and explanations given to us and on the basis of our examination of the records, the Company has not given any loans, guarantee and security or made any investments to which provisions of section 185 and 186 of the Act is applicable, and accordingly paragraph 3 (iv) of the Order is not applicable to the Company.
- 5. The Company has not accepted any deposits within the meaning of the provisions of section 73 to 76 of the Act or any other relevant provisions of the Act and the rules framed thereunder. Further, according to the information and explanations given to us, no order has been passed by the Company Law Board or National Company Law Tribunal or Reserve Bank of India or any court or any other Tribunal, in this regard.
- 6. In absence of any manufacturing activity carried out by the company, the requirement of maintenance of cost records under sub section 1 of section 148 of the Companies Act, 2013 are not applicable to the company during the year under audit.
- 7. According to the information and explanations given to us and on the examination of books of accounts:
  - (a) The undisputed statutory dues in respect of Goods and Services tax, Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Service tax, Duty of Custom, Duty of Excise, Value added Tax, Cess are not applicable to the company for the year under audit. Accordingly, reporting under this clause is not applicable to the company.
  - (b) There were no undisputed amount payable in respect of Goods and Service Tax, Provident Fund, Employees' State Insurance, Income-tax, Sales-tax, Service tax, Duty of Custom, Duty of Excise, Value added Tax, Cess and any other material statutory dues in arears as at March 31, 2023 for a period of more than six months from the date they became payable.
  - (c) There are no dues under dispute for the Income Tax, Sales Tax, Service tax, Goods and Service Tax, Customs duty, Excise Duty, and Value added tax and other material statutory dues as on 31<sup>st</sup> March, 2023.
- 8. According to the information and explanations given to us, there were no transactions relating to previously unrecorded income that were surrendered or disclosed as income in the tax assessments under the Income Tax Act, 1961 (43 of 1961) during the year.

- According to the information and explanations given to us and on the basis of our examination of the books of account, we report that:
  - (a) The company has not defaulted in repayment of the loans or other borrowings or in the payment of interest to any lender during the year.
  - (b) The Company has not been declared wilful defaulter by any bank or financial institution or other lender.
  - (c) The company has not taken any term loans from any banks or financial institutions. Hence, paragraph 9(c) of the order is not applicable;
  - (d) The funds raised on short term basis have not been utilized for the long-term purpose.
  - (e) The company has not taken any funds from any entity or person on account of or to meet the obligations of its subsidiaries, associates or joint ventures.
  - (f) The Company has not raised any loans during the year on the pledge of securities held in its associate company.
- 10. (a) The Company did not raise any money by way of initial public offer or further public offer (including debt instruments) during the year and hence reporting under this clause of the Order is not applicable to the Company.
  - (b) The Company has not made any preferential allotment or private placement of shares or convertible debentures (fully, partially or optionally convertible) during the year.
- 11. (a) To the best of our knowledge and according to the information and explanations given to us, no fraud by the Company or on the Company has been noticed or reported during the year.
  - (b) According to the information and explanations given to us, no report under sub-section (12) of section 143 of the Companies Act has been filed by the auditors in Form ADT-4 as prescribed under rule 13 of Companies (Audit and Auditors) Rules, 2014 with the Central Government, during the year.
  - (c) According to the information and explanations given to us, there is no whistle blower complaints received by the Company during the year.
- 12. The Company is not a Nidhi company and hence reporting under this clause of the Order is not applicable.
- 13. In our opinion and according to the information and explanations given to us, the company is in compliance with section 177 and 188 of the Act where applicable, for all transactions with the related party transactions have been disclosed in the financial statements, as required by the applicable accounting standards.
- 14. In our opinion and according to the information and explanations given to us, the requirements of having an internal audit system is not applicable to the company as the paid-up capital, turnover, outstanding loans/ borrowings from banks or financial institutions or outstanding deposits does not exceed the defined threshold as per the rules of the Act in the immediately preceding year. Accordingly, reporting under paragraph 3(xiv) (a) and (b) of the Order is not applicable to the Company.
- 15. According to the information and explanations given to us and based on our examination of the records of the Company, the Company has not entered into non-cash transactions with directors or persons connected with them and, hence, provisions of section 192 of the Act is not applicable to the company. Accordingly, paragraph 3(xv) of the Order is not applicable to the Company.
- 16. According to the information and explanations given to us and based on our examination of the records of the Company, we report that

- (a) The Company is not required to be registered under section 45-IA of the Reserve Bank of India Act
- (b) The Company has not conducted any non-banking or housing finance activities during the year;
- (c) The Company is a Core Investment Company, as defined in the regulations made by the Reserve Bank of India:
- (d) The Group has more than One Core Investment Company (two Core Investment Companies) as part of the Group.
- 17. The Company has not incurred cash losses in the current financial year and in the immediately preceding financial year.
- 18. There has been no resignation of the statutory auditors of the Company during the year.
- 19. On the basis of the financial ratios, ageing and expected dates of realization of financial assets and payment of financial liabilities, other information accompanying the financial statements and our knowledge of the Board of Directors and Management plans and based on our examination of the evidence supporting the assumptions, nothing has come to our attention, which causes us to believe that any material uncertainty exists as on the date of the audit report indicating that Company is not capable of meeting its liabilities existing at the date of balance sheet as and when they fall due within a period of one year from the balance sheet date. We, however, state that this is not an assurance as to the future viability of the Company. We further state that our reporting is based on the facts up to the date of the audit report and we neither give any guarantee nor any assurance that all liabilities falling due within a period of one year from the balance sheet date, will get discharged by the Company as and when they fall due.
- 20. On the basis of information and explanations given to us and based on the examination of the records provided to us, provisions of Corporate Social Responsibility ("CSR") is not applicable. Accordingly, reporting under clause 3(XX) of the Order is not applicable for the year.

For MUKESH M. SHAH & CO., **Chartered Accountants** Firm Registration No.: 106625W

Sd/-

Karnik K. Shah Partner

Membership No.: 129675

UDIN: 23129675BGXDTE4095

Place: Ahmedabad

Date: 29<sup>th</sup> April,2023

## "ANNEXURE B" TO THE AUDITORS' REPORT

Report on the Internal Financial Control clause (i) of sub-section 3 of section 143 of the Companies Act, 2013 ("the act")

We have audited the internal financial controls over financial reporting of **ZYDUS STRATEGIC INVESTMENT LIMITED** ("the company") as of March 31, 2023 in conjunction with our audit of the financial statements of the Company for the year ended on that date.

## **Management Responsibility for Internal Financial Controls**

The company's management is responsible for establishing and maintaining internal financial control based on the internal control over financial reporting criteria established by the company considering the essential components of internal control stated in the Guidance Note on audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India ["ICAI"]. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

# **Auditors' Responsibility**

Our responsibility is to express an opinion on the company's internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the "Guidance Note") and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143(10) of the Act, to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Controls and, both issued by the ICAI. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial control system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor's Judgement, including the assessment of the material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company's internal financial controls system over financial reporting.

# **Meaning of Internal Financial Controls Over Financial Reporting**

A company's internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal financial control over financial reporting includes those policies and procedures that:

- 1. pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company;
- provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and

3. provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

# Inherent limitations of Internal Financial Controls Over Financial Reporting

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

# Opinion

In our opinion, the Company has, in all material respects, an adequate internal financial controls system over financial reporting and such internal financial controls over financial reporting were operating effectively as at March 31, 2023, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For **MUKESH M. SHAH & CO.,** Chartered Accountants Firm Registration No.: 106625W

Place: Ahmedabad Date: 29<sup>th</sup> April, 2023

UDIN: 23129675BGXDTE4095

Sd/-Karnik K. Shah

Partner

Membership No.: 129675

Balance Sheet as at March 31, 2023					
Particulars	Note	IN	INR		
	No.	As at March 31			
		2023	2022		
EQUITY AND LIABILITIES:					
Shareholders' Funds:					
Share Capital	3	1,00,00,000	1,00,00,0		
Reserves and Surplus	4	4,52,515	70,8		
		1,04,52,515	1,00,70,8		
Current Liabilities:					
Trade Payables :					
Dues to Micro and Small Enterprises	5	-	-		
Dues to Other than Micro and Small Enterprises	5	10,000	10,0		
Short term provision	6	65,238	· -		
Total		1,05,27,753	1,00,80,8		
ASSETS:					
Non Current Assets:					
Long term loan and advances	7	3,600	9,4		
Current Assets:					
Cash and Cash Equivalents	[A] 8	2,62,987	68,2		
Bank Balances other than Cash and Cash Equivalents	8 [B]	1,02,61,166	1,00,03,1		
Total		1,05,27,753	1,00,80,8		
Significant Accounting Policies	2				
Notes to the Financial Statements	1 to 16				
As per our report of even date		For and on behalf	of the Board		
For Mukesh M. Shah & Co.,					
Chartered Accountants					

Chartered Accountants Firm Registration Number: 106625W

Sd/-

Karnik K. Shah Partner

Membership Number: 129675 Ahmedabad, Dated: April 29, 2023

Sd/-Nitin D. Parekh Director

DIN: 00155570

Sd/-Vishal J. Gor Director DIN: 08787850 Ahmedabad, Dated: April 29, 2023

Zydus Strategic Investments Limited Statement of Profit and Loss for the year ended March 31, 2023				
Particulars	Note	INR		
	No.	Year ended March 31		
		2023	2022	
Income:				
Other Income	9	5,09,655	3,66,660	
Total Revenue		5,09,655	3,66,660	
EXPENSES:				
Other Expenses	10	11,800	12,400	
Total Expenses		11,800	12,400	
Profit/(Loss) before Tax		4,97,855	3,54,260	
Less: Tax Expense:				
Current Tax	11	1,16,500	79,000	
Prior period tax adjustments	11	(276)		
		1,16,224	79,000	
Profit for the year		3,81,631	2,75,260	
Basic & Diluted Earning per Equity Share [EPS] [in Rupees]	12	0.38	0.28	
Significant Accounting Policies	2			
Notes to the Financial Statements	1 to 16			
As per our report of even date		For and on behalf	of the Board	

For Mukesh M. Shah & Co.,

Chartered Accountants

Firm Registration Number: 106625W

Sd/-Nitin D. Parekh Director DIN: 00155570

Sd/-

Karnik K. Shah Partner

Membership Number: 129675 Ahmedabad, Dated: April 29, 2023

Sd/-Vishal J. Gor

Director

DIN: 08787850 Ahmedabad, Dated: April 29, 2023

	Zydus Strategic Investments Limited				
	Cash Flow Statement for the year ended March 31, 2	023 INR			
		Year ended March 31			
	Particulars	2023	2022		
Α	Cash flows from operating activities:				
	Profit before Tax	3,81,631	2,75,260		
	Adjustments for:				
	[Decrease]/ Increase in other current liabilities	65,238	(2,58,451)		
	Cash generated from operations	4,46,869	16,809		
	Direct taxes paid [Net of refunds]	5,847	(4,468)		
	Net cash from operating activities	4,52,716	12,341		
В	Cash flows from investing activities:				
	Net cash used in investing activities	-	-		
С	Cash flows from financing activities:				
	Proceeds from issue of Equity Shares	-			
	Net cash from financing activities	-	-		
	Net Increase in cash and cash equivalents	4,52,716	12,341		
	Cash and cash equivalents at the beginning of the year	1,00,71,437	1,00,59,096		
	Cash and cash equivalents at the end of the year	1,05,24,153	1,00,71,437		

# Notes to the Cash Flow Statement

- The above cash flow statement has been prepared under the "Indirect method" as set out in AS-3 "Cash Flow Statement".
- 2 All figures in brackets are outflows.
- Previous year's figures have been regrouped wherever necessary.

4	Cash and cash equivalents comprise of:	INR			
		As at March 31			
		2023	2022	2021	
	a Cash and Cash Equivalents	ı	-	-	
	b Bank Balances other than Cash and Cash Equivalents	1,05,24,153	1,00,71,437	1,00,59,096	
	c Total	1,05,24,153	1,00,71,437	1,00,59,096	

As per our report of even date

For Mukesh M. Shah & Co.

**Chartered Accountants** 

Firm Registration Number: 106625W

For and on behalf of the Board

<u>Sd/-</u>

Nitin D. Parekh **Director** 

Sd/-

Karnik K. Shah

Partner

Membership Number: 129675 Ahmedabad, Dated: April 29, 2023 DIN: 00155570

Sd/-Vishal J. Gor Director

#### Zydus Strategic Investments Limited

## Note: 1-Company overview:

Zydus Strategic Investments Limited ["the Company"] [CIN: U65999GJ2020PLC114493] is subsidiary of Zydus Lifesciences Limited (Formerly known as Cadila Healthcare Limited). The Company is classified as a Core Investment Company [CIC] and is exempt from registration with Reserve Bank of India [RBI]. The registered office of the Company is located at "Zydus Corporate Park", Scheme No.63, Survey No. 536, Khoraj (Gandhinagar) Near Vaishnodevi Circle, S. G. Highway, Ahmedabad - 382481. These financial statements were authorised for issue in accordance with a resolution passed by the Board of Directors at their meeting held on April 29, 2023.

## Note: 2-Significant Accounting Policies:

## 1 Basis of Accounting:

The financial statements are prepared under the historical cost convention on the "Accrual Concept" of accountancy in accordance with the accounting principles generally accepted in India and they comply with the Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies [Accounts] Rules, 2014 and other pronouncements issued by the Institute of Chartered Accountants of India [ICAI], to the extent applicable, and with the applicable provisions of the Companies Act, 2013.

#### 2 Use of Estimates

The preparation of Financial Statements in conformity with the Accounting Standards generally accepted in India requires, the management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities as at the date of the financial statements and reported amounts of revenues and expenses for the year while actual results could differ from these estimates. Any revision to accounting estimates is recognised prospectively in current and future periods.

#### 3 Borrowing Costs

- A Borrowing costs that are directly attributable to the acquisition/ construction of a qualifying asset are capitalised as part of the cost of such assets, up to the date the assets are ready for their intended use.
- **B** Other borrowing costs are recognised as an expense in the year in which they are incurred.

#### 4 Investments:

- A Long term and strategic investments are stated at cost, less any diminution in the value other than temporary.
- **B** Current investments are stated at lower of cost and fair value determined on individual investment basis.
- C Investments in shares of foreign subsidiaries and other companies are expressed in Indian currency at the rates of exchange prevailing at the time when the original investments were made.

#### 5 Revenue Recognition:

- A Service income is recognised as per the terms of contracts with the customers when the related services are performed or the agreed milestones are achieved and are net of Goods and service tax, wherever applicable.
- **B** Interest income is recognised on time proportionate method.
- C Revenue in respect of other income is recognised when no significant uncertainty as to its determination or realisation exists.

#### 6 Foreign Currency Transactions:

- A The transactions in foreign currencies are stated at the rates of exchange prevailing on the dates of transactions.
- **B** The net gain or loss on account of exchange rate differences either on settlement or on translation of short term monetary items is recognised in the Statement of Profit and Loss.
- C Investments in foreign subsidiaries and other companies are recorded in Indian currency at the rates of exchange prevailing at the time when the investments were made.

#### 7 Taxes on Income:

- A Tax expenses comprise of current and deferred tax.
- **B** Current tax is measured at the amount expected to be paid on the basis of reliefs and deductions available in accordance with the provisions of the Income Tax Act, 1961.
- C Deferred tax reflects the impact of current year timing differences between accounting and taxable income and reversal of timing differences of earlier years. Deferred tax is measured based on the tax rates and laws that have been enacted or substantively enacted as of the balance sheet date. Deferred tax assets are recognised only to the extent there is virtual certainty that sufficient future taxable income will be available against which such deferred tax assets can be realised and are reviewed at each balance sheet date.

## 8 Provisions, Contingent Liabilities and Contingent Assets:

Provision is recognised when the Company has a present obligation as a result of past events and it is probable that the outflow of resources will be required to settle the obligation and in respect of which reliable estimates can be made. A disclosure for contingent liability is made when there is a possible obligation, that may, but probably will not require an outflow of resources. When there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote, no provision/ disclosure is made. Contingent assets are not recognised in the financial statements. Provisions and contingencies are reviewed at each balance sheet date and adjusted to reflect the correct management estimates.

		Zvdus Strategi	c Investments	Limited			
	•		Financial State				
							NR
							larch 31
Note: 3-Share Capital:						2023	2022
Authorised:							
1,000,000 [as at March 31, 2022: 1,000,000	) ] Equity Sha	res of Rs.10/- ea	ich			1,00,00,000	1,00,00,000
							1,00,00,000
Issued, Subscribed and Paid-up:							
1,000,000 [as at March 31, 2022: 1,000,000 <b>Total</b>	] Equity Sha	res of Rs.10/- ea	ich fully paid-up			1,00,00,000	1,00,00,000
lotai						1,00,00,000	1,00,00,000
A There is no change in the number of equity	shares as at	the beginning ar	nd end of the year	r.			
Number of equity shares at the begin	ning and at th	ne end of year	,			10,00,000	10,00,000
B Details of Shareholders holding more than 5							
Zydus Lifesciences Limited [For	merly known a	as Cadila Health	care Limited] Hol	ding Company		0.00.000	0.00.000
Number of Shares % to total share holding						9,00,000 90%	9,00,000 90%
Zydus Healthcare Limited						30 70	30 /0
Number of Shares						1,00,000	1,00,000
% to total share holding						10%	10%
C The Company has only one class of equity s							
holder of equity share is entitled to one vot Directors is subject to the approval of the s	•		•				
case of interim dividend. In the event of liq							
entitled to proportionate share of their hold							
preferential amounts.							
D Details of Equity Shares held by promo	oters at the	end of the yea	r March 31, 20	23 and 2022:	0/ -1		
# Promoter's Name			No. of Shares	% of total shares	% change during the		
1 Zvdus Lifesciences Limited ( Formerly know	6 17			Silaies	vear		
1 Zydus Lifesciences Limited ( Formerly know Healthcare Limited )	n as Cadila		9,00,000	90%	_		
2 Zydus Healthcare Limited			1,00,000	10%	_		
,							
Note: 4-Reserves and Surplus:							
Surplus in Statement of Profit and Loss:						70.004	(2.04.276)
Balance as per last Balance Sheet Add: Profit for the year						70,884 3,81,631	(2,04,376) 2,75,260
Balance as at the end of the year						4,52,515	70,884
Total						4,52,515	70,884
Note: 5-Trade Payables:							
Micro and Small Enterprises (*)						10.000	- 10.000
Others <b>Total</b>						10,000 10,000	10,000 10,000
(*)During the year there is no transaction with M	icro and Smal	l Enterprises ne	ither there is any	balance		10,000	10,000
or interest payable. Hence the detailed disclosure		•					
Ageing of Trade Payables :							
Bestienten	l <b>.</b>			Overdue from d	lue date of paym		
Particulars	Not due		Less than 1	1 to 2 years	2 to 3 years	More than 3 vears	Total
			year	As at March 3	1 31, 2023	years	
Undisputed Micro and Small Enterprises [MSME]	- 1	-	-	-	-	- 1	-
Undisputed Others	10,000		-	-	-	-	10,000
Disputed MSME Disputed Others	[		] -				
Total	10,000	-	-	-	-	-	10,000
Hadisantal Missa and C. H.E				As at March 3	31, 2022		
Undisputed Micro and Small Enterprises [MSME] Undisputed Others	10,000	-	-	-			10,000
Disputed MSME	-		-				-
Disputed Others Total	- 10.000		-				- 10.000
10441	10,000	-	<u> </u>	-	-	-	10,000

Zydus Strategic Investments Notes to the Financial Stat			
		II	iR
		As at M	arch 31
		2023	2022
Note: 6-Short term provision :			
Provision for Taxation [Net of advance payment of tax of INR 51,262/-]		65,238	
		65,238	
Note: 7-Long term loan and advances :			
Advance Payment of Tax		_	7,647
Balances with Statutory Authorities		3,600	1,800
Total		3,600	9,447
Note: 8-Cash and Bank Balances:			
A Cash and Cash Equivalents:		2 62 627	60.247
Balances with Banks Total		2,62,987 2,62,987	68,247 68,247
Iotal		2,02,907	00,247
B Bank Balances other than Cash and Cash Equivalents:			
Fixed deposits		1,02,61,166	1,00,03,190
·			
Note: 9-Other Income:			
Finance Income:			
Interest Income		5,09,655	3,66,660
Total		5,09,655	3,66,660
Note: 10-Other Evnenses:			
Note: 10-Other Expenses:  Legal and Professional Fees [*]		11,800	12,400
Legal and Froicestorial rices [ ]		11,000	12,400
Total		11,800	12,400
[*] Payment to the Statutory Auditors [excluding GST]:			
i - As Auditor		10,000	10,000
- For Other Services		-	
Total		10,000	10,000
Note: 11 Tay Sympassy			
Note: 11-Tax Expenses: The major components of income tax expense are:			
A Statement of profit and loss:			
Profit or loss section:			
Current income tax:			
Current income tax charge		1,16,500	79,000
Adjustments in respect of current income tax of previous year		(276)	-
		1,16,224	79,000
B Reconciliation of tax expense and accounting profit multiplied by India's dome	estic tax rate:		
Profit before tax		4,97,855	3,54,260
Enacted Tax Rate in India (%)		25.17%	26.00% 92,108
Expected Tax Expenses Adjustments for:		1,25,300	92,100
Others (Including prior period tax adjustments)		(9,076)	(13,108
Tax Expenses as per Statement of Profit and Loss		1,16,224	79,000
Note: 12-Calculation of Earnings per Equity Share [EPS]:			
The numerators and denominators used to calculate the basic and diluted EPS are as follows:			
A Profit attributable to Shareholders	INR	3,81,631	2,75,260
B Weighted average number of Equity shares outstanding during the year	Numbers	10,00,000	10,00,000
C Nominal value of equity share D Basic and adjusted EPS	INR INR	10 0.38	10 0.28
D basic and adjusted EFS	TIVIX	0.50	0.20
Note: 13-Related Party Transactions:			
A Name of the Related Parties and Nature of the Related Party Relationship with who	om transactions have taken pl	ace:	
a Holding Company	Zydus Lifesciences Limited [Form	nerly known as Cadi	la Healthcare
	Limited]		
b Fellow Subsidiary Companies/entities			
Zydus Healthcare Limited	Nesher Pharmaceuticals (USA) L	LC [USA]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited	ZyVet Animal Health Inc. [USA]		
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA]	6A]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA]	6A]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [USA]	5A]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA]	5A] 5A]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [u	5A] 5A] N] JSA]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USX Zydus Therapeutics Inc. [ZTI] [U Zydus Healthcare S.A. (Pty) Ltd	SA] SA] JSA] [South Africa]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [US Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L	SA]  SA]  JSA]  [South Africa]  td [South Africa]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [I Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt	SA]  SA]  JSA]  [South Africa]  td [South Africa]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [U Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt Zydus France, SAS [France]	5A] N] JSA] [South Africa] td [South Africa] y) Ltd [South Africa]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus VTEC Limited	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [I Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt Zydus France, SAS [France] Laboratorios Combix S.L. [Spain	5A] N] JSA] [South Africa] td [South Africa] y) Ltd [South Africa]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus VTEC Limited Zydus Foundation	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [US/ Zydus Therapeutics Inc. [ZTI] [U Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt Zydus France, SAS [France] Laboratorios Combix S.L. [Spain Etna Biotech S.R.L. [Italy]	SA]  SA]  JSA]  [South Africa]  td [South Africa]  y) Ltd [South Africa]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus VTEC Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [I Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt Zydus France, SAS [France] Laboratorios Combix S.L. [Spain	SA]  [SA]  JSA]  [South Africa]  td [South Africa]  y) Ltd [South Africa]  ]  A De CV [Mexico]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus VTEC Limited Zydus Foundation	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ETI] [I Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt Zydus France, SAS [France] Laboratorios Combix S.L. [Spain Etna Biotech S.R.L. [Italy] Zydus Pharmaceuticals Mexico S	SA]  SA]  SA]  JSA]  [South Africa]  td [South Africa]  y) Ltd [South Africa]  ]  SA De CV [Mexico]  tes Company SA De C.	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus VTEC Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm Zydus International Private Limited [Ireland]	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [I Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) LS cript Management Services (Pt Zydus France, SAS [France] Laboratorios Combix S.L. [Spain Etna Biotech S.R.L. [Italy] Zydus Pharmaceuticals Mexico S Zydus Pharmaceuticals Mexico Services (Ptal)	SA] SA] JSA] JSA] [South Africa] td [South Africa] y) Ltd [South Africa] ] SA De CV [Mexico] tes Company SA De C.	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Lanka (Private) Limited [Sri Lanka] Zydus Nikkho Farmaceutica Ltda. [Brazii]	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals Inc. [USA] Hercon Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [I Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt Zydus France, SAS [France] Laboratorios Combix S.L. [Spain Etna Biotech S.R.L. [Italy] Zydus Pharmaceuticals Mexico S Zydus Worldwide DMCC [Dubai] Zydus Wellness International DN Zydus Wellness [BD] Pvt Ltd [Ba	SA]  SA]  JSA]  [South Africa]  td [South Africa]  y) Ltd [South Africa]  ]  SA De CV [Mexico]  ces Company SA De C.  MCC [Dubai]  angladesh]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus VTEC Limited Zydus VTEC Limited Zydus VTEC Limited Zydus Netneraceuticals and Investments, a Partnership Firm Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Lanka (Private) Limited [Sri Lanka] Zydus Nikkho Farmaceutical Ltda. [Brazil] Alidac Healthcare (Myanmar) Limited [Myanmar]	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals LLC [US Viona Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [I Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt Zydus France, SAS [France] Laboratorios Combix S.L. [Spain Etna Biotech S.R.L. [Italy] Zydus Pharmaceuticals Mexico Servic Zydus Worldwide DMCC [Dubai] Zydus Wellness International DN Zydus Wellness [BD] Pvt Ltd [BS Zynext Ventures PTE. LTD. [Sing	SA]  SA]  JSA]  [South Africa]  td [South Africa]  y) Ltd [South Africa]  ]  SA De CV [Mexico]  ces Company SA De C.  MCC [Dubai]  angladesh]  gapore]	
Zydus Healthcare Limited German Remedies Pharmaceuticals Private Limited Zydus Wellness Limited Zydus Wellness Products Limited Liva Nutritions Limited Liva Investment Limited Liva Investment Limited Zydus Animal Health and Investments Limited Dialforhealth Unity Limited Dialforhealth Greencross Limited Violio Healthcare Limited Zydus Pharmaceuticals Limited Biochem Pharmaceutical Private Limited Zydus Foundation M/s. Recon Pharmaceuticals and Investments, a Partnership Firm Zydus International Private Limited [Ireland] Zydus Netherlands B.V. [the Netherlands] Zydus Lanka (Private) Limited [Sri Lanka] Zydus Nikkho Farmaceutica Ltda. [Brazil]	ZyVet Animal Health Inc. [USA] Zydus Healthcare (USA) LLC [US Sentynl Therapeutics Inc. [USA] Zydus Noveltech Inc. [USA] Hercon Pharmaceuticals Inc. [USA] Hercon Pharmaceuticals Inc. [USA] Zydus Therapeutics Inc. [ZTI] [I Zydus Healthcare S.A. (Pty) Ltd Simayla Pharmaceuticals (Pty) L Script Management Services (Pt Zydus France, SAS [France] Laboratorios Combix S.L. [Spain Etna Biotech S.R.L. [Italy] Zydus Pharmaceuticals Mexico S Zydus Worldwide DMCC [Dubai] Zydus Wellness International DN Zydus Wellness [BD] Pvt Ltd [Ba	SA] SA] SA] JSA] [South Africa] td [South Africa] y) Ltd [South Africa] ] SA De CV [Mexico] ces Company SA De C. MCC [Dubai] angladesh] japore] ed [UK]	

## **Zydus Strategic Investments Limited** Notes to the Financial Statements

## Note: 13-Related Party Transactions: Continued..

c Directors:

Mr. Nitin D. Parekh Director Mr. Harish R. Sadana Director Mr. Vishal J. Gor Director

# **B Transactions with Related Parties:**

There were no transaction with parties mentioned in Note 12-A [a,b,c]

Note: 14-Analytical Ratios:

	tote. 14-Allalytical Ratios.						
#	Ratio	Numerator	Denominator	FY 22-23	FY 21-22	% Change	
1	Current Ratio [*]	Current Assets	Current Liabilities	139.9	1,007.1	-86%	
2	Debt-Equity Ratio	Total Debt	Shareholder's Equity	N.A.	N.A.	N.A.	
3	Debt Service Coverage Ratio	Earnings available for debt service	Finance cost + Repayment of debt	N.A.	N.A.	N.A.	
4	Return on Equity Ratio [#]	Net profit after taxes + exceptional items	Average Shareholder's Equity	3.72%	2.77%	34%	
5	Inventory turnover ratio	Net Sales	Average Inventory	N.A.	N.A.	N.A.	
6	Trade Receivables turnover ratio	Net Sales	Average Trade Receivables	N.A.	N.A.	N.A.	
7	Trade payables turnover ratio	Net Purchases and Other Expenses	Average Trade Payables	N.A.	N.A.	N.A.	
8	Net capital turnover ratio	Net Sales	Average Working Capital	N.A.	N.A.	N.A.	
9	Net profit ratio	Net profit after taxes + exceptional items	Net Sales	N.A.	N.A.	N.A.	
10	Return on Capital employed [#]	Earnings before interest and taxes	Average Capital Employed	4.85%	3.57%	36%	
11	Return on investment	Income from investments during the year	Time weighted average of investments	5.1%	4.4%	15%	

[\*] Mainly due to increase in tax provision

 $\cline{figure 1.5}$  Mainly due to increase in profit on account of interest income.

# Note: 15-Disclosure of transactions with Struck off Companies:

The Company did not have any material transaction with companies struck off under Section 248 of the Companies Act, 2013 or Section 560 of Companies Act, 1956 during the current and previous financial year.

Note: 16:

Previous year's figures have been regrouped/ reclassified wherever necessary to correspond with the current year's classifications/ disclosure.

Signatures to Significant Accounting Policies and Notes 1 to 16 to the Financial Statements

For and or

As per our report of even date For Mukesh M. Shah & Co.,

Chartered Accountants Firm Registration Number: 106625W For and on behalf of the Board

Sd/-Nitin D. Parekh Director

DIN: 00155570

Sd/-

Karnik K. Shah Partner Membership Number: 129675 Ahmedabad, Dated: April 29, 2023

Sd/-Vishal J. Gor Director DIN: 08787850 Ahmedabad, Dated: April 29, 2023